Inaxaplin vs MZE829

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: APOL1 (Apolipoprotein L1) · full Chronic Kidney Disease pipeline

Inaxaplin

Developed by Vertex Pharmaceuticals

Phase 2/3 in Chronic Kidney Diseasesmall molecule
Weak signal

NCT06794996 · Phase 2 · completed

This is an unblinded, single-arm study with no comparison group, and no results have been posted yet.

Next expected readout: June 2028 · NCT05312879 (registry estimate)

Reported efficacy

Percent Change in Urine Albumin-Creatinine Ratio (UACR) (Baseline and At Week 13): Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22). (not_applicable)

Result source: NCT06794996

MZE829

Developed by Maze Therapeutics

Phase 2 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInaxaplinMZE829
Kidney composite outcome—Trial running · NCT05312879—Not reported
UACR, % change—Trial running · NCT05312879—Not reported
eGFR slope—Trial running · NCT05312879—Not reported
Haemoglobin, change—Trial running · NCT05312879—Not reported

Kidney composite outcome

Inaxaplin
—Trial running · NCT05312879
MZE829
—Not reported

UACR, % change

Inaxaplin
—Trial running · NCT05312879
MZE829
—Not reported

eGFR slope

Inaxaplin
—Trial running · NCT05312879
MZE829
—Not reported

Haemoglobin, change

Inaxaplin
—Trial running · NCT05312879
MZE829
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MZE829: no structured comparison results are available for Chronic Kidney Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Inaxaplin
Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22). NCT06794996 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result
The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3). NCT04340362 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inaxaplin's landscape · MZE829's landscape